Presentan respuestas "prometedoras" de un inhibidor para cáncer colorrectal metastático
Researchers at VHIO have presented the first dataset on combining sotorasib, an inhibitor targeting the KRASG12C mutation, with anti-EGFR drugs and chemotherapy for metastatic colorectal cancer. The treatment demonstrates a tolerable safety profile and promising response rates, indicating that this combination can effectively counteract resistance mechanisms often associated with the inhibitor alone. This approach offers significant therapeutic potential for patients harboring the KRASG12C mutation, a genetic alteration present in approximately three percent of colorectal cancer cases. By integrating targeted therapy with established chemotherapy and EGFR inhibition, the protocol achieves high disease control rates, suggesting a viable path forward for previously untreated patients with this specific molecular subtype. This article is highly relevant to open data as it highlights the critical role of transparent clinical data sharing in advancing precision oncology. Publishing these initial results fosters reproducibility and allows the broader scientific community to validate findings, accelerate collaborative research, and refine future trials, ultimately promoting equity in access to effective cancer treatments through shared knowledge.
Source: heraldo.esPublished on 2024-09-16
Related news
- Inai finca confianza en Claudia Sheinbaum ante amenaza desaparecer
- Abu Dhabi: $1 Million-Prize Drone Race To Take Place In 2025 How To Register
- Al menos 74 muertos y 89 desaparecidos por las inundaciones en Birmania
- Servicios de Salud lidera en participación ciudadana a nivel estatal
- Inflation expected to ease to 2.1%, lowest level since March 2021: economists